Britol-Myers Squibb recently appointed Murdo Gordon its new EVP and chief commercial officer.
Gordon began his term in the newly created position on June 21.
Gordon’s responsibilities include overseeing the execution of commercial strategy spanning across all geographies associated with the company while also leading the company’s Worldwide Markets and the newly-formed Worldwide Commercialization team.
“Murdo has demonstrated tremendous success driving commercial excellence at Bristol-Myers Squibb, and built strong relationships with our markets across the world,” CEO Dr. Giovanni Caforio said. “Murdo has made significant contributions to our success in immuno-oncology and Eliquis, and I am confident his leadership will help drive continued growth and deliver our medicines to more patients faster.”
Gordon, who recently co-led the commercial organization as Head of Worldwide Markets, will continue reporting to Caforio and remain a part of the leadership team. He began his career with Bristol-Myers Squibb in 1989. He was positioned in Canada his first 14 years with the company, holding positions of increasing importance within the sales and marketing teams. Gordon joined the U.S. operations of the company in 2003. Once in the U.S., he held positions of senior commercial leadership in cardiovascular, neuroscience and market access.